Related Experiment Video
Updated: Jul 2, 2026
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
Pretreatment SUVmax Stratifies the Benefit of Consecutive Daily SBRT in Early-Stage Non-Small Cell Lung Cancer
Yupeng Di1, Haifeng Pang2, Xuan Wang2
1Department of radiation protection medicine, School of Preventive Medicine, Fourth Military Medical University, Xi'an, China; Ministry of Education Key Lab of Hazard Assessment and Control in Special Operational Environment, Xi'an, China; Department of Radiation Oncology, Air Force Medical Center, PLA, Beijing, China.
Objective:
To investigate the prognostic value of pretreatment SUVmax in early-stage NSCLC treated with stereotactic body radiotherapy (SBRT) and evaluate whether metabolic activity modulates the impact of overall treatment time (OTT) on outcomes.
Methods:
We retrospectively analyzed 186 patients with stage I NSCLC treated with SBRT (48 Gy/4 fractions). Patients were stratified into high (SUVmax ≥ 5.0, n = 73) and low (SUVmax < 5.0, n = 113) metabolic groups. Schedules were categorized as consecutive (OTT 4-5 days) or non-consecutive (OTT 6-10 days). Primary endpoints were local control (LC) and overall survival (OS).
Results:
With a median follow-up of 41 months, high SUVmax was associated with inferior outcomes; the 3-year LC rates were 92.1% in the low metabolic group compared to 63.4% in the high metabolic group (P < .0001). On multivariate analysis, SUVmax ≥ 5.0 independently predicted local failure (HR 3.70, 95% CI, 1.48-9.24, P = .005) and mortality (HR 2.38, 95% CI, 1.41-4.01, P = .001). Crucially, a formal interaction test revealed that metabolic activity significantly modulated the impact of scheduling on LC (P-interaction = .042). Subgroup analysis demonstrated that consecutive treatment significantly improved LC in the high-SUVmax group (P = .035), whereas no significant difference between schedules was observed in the low-SUVmax group (P = .57).
Conclusion:
Pretreatment SUVmax is a robust prognostic biomarker for SBRT outcomes. High-metabolic tumors exhibit heightened sensitivity to treatment prolongation, likely driven by factors such as accelerated repopulation during gaps. Consequently, relatively short or consecutive SBRT courses may be beneficial for this "high-risk" metabolic subgroup. However, biological prioritization must be balanced against safety; non-consecutive schedules remain viable for indolent tumors and are mandatory when technical limitations, prior radiotherapy, or central/ultra-central tumor locations preclude the safe delivery of highly compressed ablative doses.
